Altimmune's pemvidutide reduces liver fibrosis markers in Phase 2b MASH trial

Bitget2026/10/19 12:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Altimmune will present new pemvidutide data at AASLD’s The Liver Meeting in Denver on November 5-9, 2026.
The 48-week Phase 2b IMPACT study in MASH showed improvements in liver fibrosis and inflammation markers compared with placebo.
Gastrointestinal adverse events were mild to moderate, with no severe cases reported; treatment discontinuations due to adverse events were lower than placebo.
Preclinical hamster data showed reduced alcohol intake, supporting further clinical investigation in alcohol use disorder and alcohol-associated liver disease.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altimmune Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190800PRIMZONEFULLFEED9848007) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Altimmune's pemvidutide reduces liver fibrosis markers in Phase 2b MASH trial

You may also like

Crypto prices